Global /Australia /Healthcare /Biotechnology /CMB

Cambium Bio Ltd.

CMB

• ASX: CMB • Delayed

0.4200AUD -6.7%

0.2970 USD

As of 19 June 2026, Cambium Bio Ltd. has a market cap of $8.63M USD, ranking #42067 globally and #1377 in Australia. It ranks #3723 in the Healthcare sector, and #731 in the Biotechnology industry.

Global Rank

42067

Country Rank

1377

Sector Rank

3723

Industry Rank

731

Key Stats

Market Cap

$8.63MUSD

12.3M AUD

Company Profile

Country (HQ)

Australia

Sector

Healthcare

Industry

Biotechnology

CEO

Karolis Rosickas open_in_new

Founded

2013

Website

cambium.bio open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-6.7%	-2.2%	-6.2%	-25%	-7.2%	-4.3%	55%	-5%	-94%

News

Markets

Exchange	Ticker	Price	Quotes
Australian Securities Exchange (ASX) MIC: XASX PRIMARY	CMB Cambium Bio Ltd ISIN: AU0000327769 Shares Out.: Shares Outstanding: 27.332M¹ Shares Float: 26.508M² TV: TradingView: ASX: CMB SA: Stock Analysis: ASX: CMB YF: Yahoo Finance: CMB.AX GF: Google Finance: ASX: CMB BA: Barron's: CMB MS: Morningstar: XASX: CMB	0.4200 AUD	TV: TradingView: ASX: CMB SA: Stock Analysis: ASX: CMB YF: Yahoo Finance: CMB.AX GF: Google Finance: ASX: CMB BA: Barron's: CMB MS: Morningstar: XASX: CMB

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Cambium Bio Ltd.

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.

Similar Companies

Industry: Biotechnology (Australia)

Name	Market Cap (USD) diff.	PE	Country
CSL Ltd. ASX: CSL	$42.27B 60.27B AUD 490K%	29.3	Australia
Telix Pharmaceuticals Ltd. ASX: TLX	$3.57B 5.09B AUD 41K%	-	Australia
Mesoblast Ltd. ASX: MSB	$2.02B 2.88B AUD 23K%	-	Australia
PolyNovo Ltd. ASX: PNV	$489.42M 697.75M AUD 6K%	71.8	Australia
Kazia Therapeutics Ltd. NASDAQ: KZIA	$141.64M 2K%	-	Australia
Immutep Ltd. ASX: IMM	$65.12M 92.84M AUD 655%	-	Australia

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 2M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 2M%	19.0	United States
argenx SE EBR: ARGX	$47.76B 41.39B EUR 554K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.23B 68.19T KRW 513K%	35.5	South Korea
Lonza Group AG SIX: LONN	$42.29B 33.71B CHF 490K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$27.74B 42.76T KRW 321K%	43.8	South Korea

chevron_leftBack